Compared to previously used TM4SF1 or EpCAM targeting CAR-Ts, the anti-CEA CAR-Ts displayed greater anti-tumour abilities as wells as reduction in antigen escape effects (Riccardo et al., 2018). The gene discussed is CEACAM5; the disease is neoplasm.